Literature DB >> 9350051

Uptake and metabolism of lipoprotein-X in mesangial cells.

E G Lynn1, P C Choy, A Magil, K O.   

Abstract

Progressive glomerulosclerosis is a major complication in patients with familial lecithin:cholesterol acyltransferase (LCAT) deficiency. The lack of LCAT activity results in the accumulation of an abnormal lipoprotein, lipoprotein-X (Lp-X), in the plasma of these patients. Lipoprotein-X contains high levels of unesterified cholesterol and phosphatidylcholine. Lp-X may play a role in the accumulation of lipids in the kidney, which in turn may lead to glomerulosclerosis. The objective of this study is to examine the uptake and metabolism of Lp-X by rat mesangial cells. Our results suggest that Lp-X is taken up by mesangial cells and that the lipids in Lp-X are metabolized. Lysosomes containing unesterified cholesterol and phosphatidylcholine, in a molar ratio similar to Lp-X, were synthesized to investigate the roles individual apolipoproteins (apo CI, II, III and E) play in the uptake of Lp-X. Both apo CI and CIII inhibited its uptake while apo CII (1.5 fold) and E (4 fold) stimulated the uptake of Lp-X. Very low density lipoprotein (VLDL) and low density lipoprotein (LDL) inhibited Lp-X uptake by mesangial cells. However, at higher concentrations of high density lipoprotein (HDL), the uptake of Lp-X was stimulated. Proteoglycans have an important role in regulating the uptake of Lp-X, while cytoskeleton-dependent phagocytosis and the scavenger receptor do not appear to be involved.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9350051     DOI: 10.1023/a:1006865420286

Source DB:  PubMed          Journal:  Mol Cell Biochem        ISSN: 0300-8177            Impact factor:   3.396


  38 in total

1.  Effects of low-density lipoproteins on mesangial cell growth and viability in vitro.

Authors:  D C Wheeler; J W Persaud; R Fernando; P Sweny; Z Varghese; J F Moorhead
Journal:  Nephrol Dial Transplant       Date:  1990       Impact factor: 5.992

2.  Immunohistochemical and biochemical detection of low density lipoprotein receptors in cultured rat mesangial cells.

Authors:  H Ito; M Chimata; M Oka; Y Suzuki; N Hamada; M Fujimaki; K Oda; K Fujisawa; T Teramoto; K Nakamura
Journal:  Nephron       Date:  1995       Impact factor: 2.847

3.  Liposomes with entrapped doxorubicin exhibit extended blood residence times.

Authors:  M B Bally; R Nayar; D Masin; M J Hope; P R Cullis; L D Mayer
Journal:  Biochim Biophys Acta       Date:  1990-03-30

4.  Improved methods for culturing rat glomerular cells.

Authors:  P A Harper; J M Robinson; R L Hoover; T C Wright; M J Karnovsky
Journal:  Kidney Int       Date:  1984-12       Impact factor: 10.612

5.  Renal transplantation in patients with familial lecithin: cholesterol-acetyltransferase deficiency.

Authors:  A L Flatmark; T Hovig; E Myhre; E Gjone
Journal:  Transplant Proc       Date:  1977-09       Impact factor: 1.066

Review 6.  Cellular mechanisms of lipid injury in the glomerulus.

Authors:  D Schlondorff
Journal:  Am J Kidney Dis       Date:  1993-07       Impact factor: 8.860

Review 7.  Interactions between lipoproteins, glomerular cells and matrix.

Authors:  D C Wheeler; R S Chana
Journal:  Miner Electrolyte Metab       Date:  1993

Review 8.  Focal and segmental glomerulosclerosis: analogies to atherosclerosis.

Authors:  J R Diamond; M J Karnovsky
Journal:  Kidney Int       Date:  1988-05       Impact factor: 10.612

9.  Recombinant lecithin:cholesterol acyltransferase containing a Thr123-->Ile mutation esterifies cholesterol in low density lipoprotein but not in high density lipoprotein.

Authors:  K O; J S Hill; X Wang; P H Pritchard
Journal:  J Lipid Res       Date:  1993-01       Impact factor: 5.922

10.  Cold labelled substrate and estimation of cholesterol esterification rate in lecithin cholesterol acyltransferase radioassay.

Authors:  M Dobiásová; M Schützová
Journal:  Physiol Bohemoslov       Date:  1986
View more
  6 in total

Review 1.  Lecithin cholesterol acyltransferase: an anti- or pro-atherogenic factor?

Authors:  Xavier Rousset; Robert Shamburek; Boris Vaisman; Marcelo Amar; Alan T Remaley
Journal:  Curr Atheroscler Rep       Date:  2011-06       Impact factor: 5.113

2.  Corticosteroid treatment of kidney disease in a patient with familial lecithin-cholesterol acyltransferase deficiency.

Authors:  Przemysław Miarka; Barbara Idzior-Waluś; Marek Kuźniewski; Małgorzata Waluś-Miarka; Tomasz Klupa; Władysław Sułowicz
Journal:  Clin Exp Nephrol       Date:  2011-02-16       Impact factor: 2.801

3.  Progression of chronic kidney disease in familial LCAT deficiency: a follow-up of the Italian cohort.

Authors:  Chiara Pavanello; Alice Ossoli; Marcello Arca; Laura D'Erasmo; Giuliano Boscutti; Loreto Gesualdo; Tiziano Lucchi; Tiziana Sampietro; Fabrizio Veglia; Laura Calabresi
Journal:  J Lipid Res       Date:  2020-09-30       Impact factor: 5.922

4.  Lipoprotein X Causes Renal Disease in LCAT Deficiency.

Authors:  Alice Ossoli; Edward B Neufeld; Seth G Thacker; Boris Vaisman; Milton Pryor; Lita A Freeman; Christine A Brantner; Irina Baranova; Nicolás O Francone; Stephen J Demosky; Cecilia Vitali; Monica Locatelli; Mauro Abbate; Carlamaria Zoja; Guido Franceschini; Laura Calabresi; Alan T Remaley
Journal:  PLoS One       Date:  2016-02-26       Impact factor: 3.240

5.  C. trachomatis-infection accelerates metabolism of phosphatidylcholine derived from low density lipoprotein but does not affect phosphatidylcholine secretion from hepatocytes.

Authors:  Grant M Hatch; Grant McClarty
Journal:  BMC Microbiol       Date:  2004-02-17       Impact factor: 3.605

6.  LCAT protects against Lipoprotein-X formation in a murine model of drug-induced intrahepatic cholestasis.

Authors:  Marcelo J A Amar; Lita A Freeman; Takafumi Nishida; Maureen L Sampson; Milton Pryor; Boris L Vaisman; Edward B Neufeld; Sotirios K Karathanasis; Alan T Remaley
Journal:  Pharmacol Res Perspect       Date:  2019-12-29
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.